| 000 | 01847 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514071412.0 | ||
| 264 | 0 | _c20040406 | |
| 008 | 200404s 0 0 eng d | ||
| 022 | _a0264-410X | ||
| 024 | 7 |
_a10.1016/s0264-410x(03)00158-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGilbert, P B | |
| 245 | 0 | 0 |
_aLong-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. _h[electronic resource] |
| 260 |
_bVaccine _cJun 2003 |
||
| 300 |
_a2933-47 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAIDS Vaccines _xadverse effects |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aCanarypox virus _xgenetics |
| 650 | 0 | 4 | _aClinical Trials, Phase I as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV-1 _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNational Institutes of Health (U.S.) |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aSalmonella _xgenetics |
| 650 | 0 | 4 | _aTime |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aVaccines, Subunit _xadverse effects |
| 650 | 0 | 4 |
_aVaccines, Synthetic _xadverse effects |
| 650 | 0 | 4 |
_aVaccinia virus _xgenetics |
| 700 | 1 | _aChiu, Y-L | |
| 700 | 1 | _aAllen, M | |
| 700 | 1 | _aLawrence, D N | |
| 700 | 1 | _aChapdu, C | |
| 700 | 1 | _aIsrael, H | |
| 700 | 1 | _aHolman, D | |
| 700 | 1 | _aKeefer, M C | |
| 700 | 1 | _aWolff, M | |
| 700 | 1 | _aFrey, S E | |
| 773 | 0 |
_tVaccine _gvol. 21 _gno. 21-22 _gp. 2933-47 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0264-410x(03)00158-0 _zAvailable from publisher's website |
| 999 |
_c12583228 _d12583228 |
||